Elasmogen is a therapeutic biologics company developing dual targeting products for difficult-to-treat autoimmune diseases. Our lead, first-in-class product, ELN28, is designed to target to the site of inflammation where it neutralises soluble TNFa whilst specifically and safely delivering Janus kinase inhibitor. Our mission is to progress ELN28 to the clinic, breaking the efficacy ceiling on current therapies, to treat autoimmune patients with poorly controlled disease by providing rapid control and long-term remission.
Company Details
- Employees
- 11
- Founded
- -
- in****@****gen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.elasmogen.com
Elasmogen Ltd Questions
Elasmogen Ltd's website is http://www.elasmogen.com
Elasmogen Ltd's LinkedIn profile is https://www.linkedin.com/company/elasmogen-ltd
Elasmogen Ltd has
11 employees.
View email and phone details for 11
employees at Elasmogen Ltd.
Elasmogen Ltd's industry is
Biotechnology Research
Elasmogen Ltd's top competitors are
Tc Biopharm,
Enterobiotix,
Taurx,
Quell Therapeutics,
Ingenza Ltd,
Amphista Therapeutics Limited,
Novabiotics Ltd,
Roukenbio,
Nanosyrinx,
Epitogenx.
Elasmogen Ltd's support email address is info@elasmogen.com
Elasmogen Ltd's categories are Biotechnology Research
Elasmogen Ltd's founding year is 2016
